Application of Listing Proceeds to Growth Investment and Working Capital
First written in FY2021-Q2. 2 of 4 entries say "Reframed", first in FY2022-Q3. Latest entry: FY2023-Q3.
Axxzia moved to the "Worse" side of this theme in 2022, 3 years before the typical company in this theme (2025).
14 other companies' latest entry also says "Reframed".
- FY2023-Q3ReframedAnnual report
「Accordingly, the company has changed the allocation so that ¥512 million will be used by the fiscal year ending July 2024 for capital investment to establish its own logistics facility.」
Regarding the use of listing proceeds, ¥512 million has been reallocated from the ¥2,759 million invested in highly secure financial products and similar instruments to establish the company's own logistics facility. - FY2022-Q3ReframedAnnual report
「Of the ¥4,023 million raised when the company listed on the Mothers market of the Tokyo Stock Exchange on 18 February 2021, ¥2,000 million was scheduled to be allocated by the fiscal year ending July 2023 to capital investment for construction of a new plant. However, the company decided to allocate the funds to the acquisition of shares in 株式会社ユイット・ラボラトリーズ, as this would shorten the time required to construct and commence operations at the plant and reduce the risks associated with acquiring manufacturing expertise and securing personnel before the plant became operational.」
Regarding the use of listing proceeds, the planned allocation of ¥2,000 million for construction of a new plant has been changed to ¥860 million for an M&A transaction involving a company with plant capabilities. The amount invested in highly secure financial products and similar instruments from the remaining funds has also been changed from ¥1,619 million to ¥2,759 million. - FY2021RestatedAnnual report
「The company's main working capital needs include research and development investment for launching new products, opening stores, capital investment to improve productivity, and advertising investment to increase brand awareness. The main source of funds is income from sales of cosmetics and health supplements.」
It continues to describe post-listing funding needs as research and development, stores, capital investment, advertising, and working capital. - FY2021-Q2First statedAnnual report
「The funds are planned to be allocated to capital investment for construction of a new plant, capital investment for opening new company-operated stores, research and development investment for launching products, and increased working capital associated with business expansion.」
It identifies the specific uses of funds raised through the public offering as growth investment and working capital associated with business expansion.